ClinicalTrials.gg

Program

NWRD09

A development code. Also written as “NWRD09 administered by intramuscular injection”, “NWRD09 Injection” and “NWRD09 injection”.

Its studies are mostly in Squamous Intraepithelial Lesions · Carcinoma in Situ, led by Newish Biotech (Wuxi).

Furthest: phase 2, since Apr 10, 20266 company-led studies, 6 open or runningNext primary completion: Dec 30, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Newish Biotech (Wuxi)66 open or runningphase 2since Apr 10, 2026Dec 16, 2024Dec 30, 2026phase 1 · NCT07710664

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 16, 2024First study: no phase study in Carcinoma in SituFirst studyNCT06741150 · 18 planned · China
  2. Jun 24, 2025Phase 1 study in Squamous Intraepithelial LesionsNCT07047989 · 9 planned · China
  3. Jul 21, 2025No phase study in Carcinoma in SituNCT07092007 · 18 planned · China
  4. Apr 10, 2026Phase 2 study in Persistent HPV16 InfectionPhase 2 reachedNCT07536282 · 78 planned · United States
  5. Jul 8, 2026Phase 2 study in Squamous Intraepithelial LesionsNCT07712692 · 156 planned · China
  6. Jul 13, 2026Phase 1 study in Persistent HPV16 InfectionNCT07710664 · 10 planned · China

Ahead

  1. Dec 30, 2026Primary completion: phase 1 study in Persistent HPV16 InfectionNCT07710664
  2. Jun 30, 2027Primary completion: phase 2 study in Squamous Intraepithelial LesionsNCT07712692
  3. Sep 2027Primary completion: phase 2 study in Persistent HPV16 InfectionNCT07536282

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07710664Persistent HPV16 Infection · China1RecruitingDec 30, 202610
NCT07712692Squamous Intraepithelial Lesions · China2Not yet recruitingJun 30, 2027156
NCT07536282Persistent HPV16 Infection · United States2Not yet recruitingSep 202778
NCT07092007Carcinoma in Situ · China–RecruitingDec 31, 202518
NCT07047989Squamous Intraepithelial Lesions · China1RecruitingJul 31, 20269
NCT06741150Carcinoma in Situ · China–RecruitingDec 31, 202518

How it is read

Names in the registry

  • “NWRD09”, 2 entries
  • “NWRD09 administered by intramuscular injection”, 2 entries
  • “NWRD09 Injection”, 1 entry
  • “NWRD09 injection”, 1 entry

Codes read as this program: NWRD09.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
NWRD09 (Newish Biotech (Wuxi)): development program | ClinicalTrials.gg